Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

ClinicalTrials.gov ID: NCT02199691

Public ClinicalTrials.gov record NCT02199691. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human papilloma virus (HPV) vaccine. Primary objective: * To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine when MenACYW Conjugate vaccine was given alone compared to those when MENVEO vaccine was given alone. Secondary objective: * To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with Tdap and HPV vaccines, compared to those when it was given alone. * To evaluate the antibody responses to the antigens present in Tdap vaccine, when Tdap vaccine was given concomitantly with MenACYW Conjugate vaccine and HPV vaccine, compared to those when Tdap vaccine was given with HPV vaccine only. * To evaluate the antibody responses to the antigens present in HPV vaccine after the 3-dose series, when the first dose of HPV vaccine is given concomitantly with MenACYW Conjugate vaccine and Tdap vaccine, compared to those when the first dose of HPV vaccine is given with Tdap vaccine only. Observational objective: * To describe the safety profile of MenACYW Conjugate vaccine, compared to that of the licensed vaccine MENVEO®, and when MenACYW Conjugate vaccine was given with Tdap and HPV vaccines.

Study identification

NCT ID
NCT02199691
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
1,715 participants

Conditions and interventions

Eligibility (public fields only)

Age range
10 Years to 17 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 21, 2014
Primary completion
Oct 1, 2015
Completion
Oct 1, 2015
Last update posted
Apr 3, 2022

2014 – 2015

United States locations

U.S. sites
35
U.S. states
15
U.S. cities
31
Facility City State ZIP Site status
Not listed Birmingham Alabama 35235 —
Not listed Huntsville Alabama 35802 —
Not listed Downey California 90241 —
Not listed San Diego California 92103 —
Not listed Miami Beach Florida 33141 —
Not listed Wichita Kansas 67205 —
Not listed Bardstown Kentucky 40004 —
Not listed Nicholasville Kentucky 40356 —
Not listed Columbia Maryland 21075 —
Not listed Lincoln Nebraska 68504 —
Not listed Lincoln Nebraska 68505 —
Not listed Lincoln Nebraska 68516 —
Not listed Cleveland Ohio 44121 —
Not listed Dayton Ohio 45414 —
Not listed Norman Oklahoma 73069 —
Not listed Erie Pennsylvania 16505 —
Not listed Charleston South Carolina 29414 —
Not listed Kingsport Tennessee 37660 —
Not listed Tullahoma Tennessee 37388 —
Not listed Layton Utah 84041 —
Not listed Orem Utah 84057 —
Not listed Payson Utah 84651 —
Not listed Provo Utah 84064 —
Not listed Roy Utah 84067 —
Not listed Salt Lake City Utah 84109 —
Not listed Salt Lake City Utah 84124 —
Not listed South Jordan Utah 84095 —
Not listed Spanish Fork Utah 84660 —
Not listed Syracuse Utah 84075 —
Not listed West Haven Utah 84401 —
Not listed West Jordan Utah 84088 —
Not listed Charlottesville Virginia 22902 —
Not listed Midlothian Virginia 23113 —
Not listed Spokane Washington 99204 —
Not listed Spokane Washington 99218 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02199691, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2022 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02199691 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →